OncoMatch/Clinical Trials/NCT03150576
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
Is NCT03150576 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Olaparib and Paclitaxel and Carboplatin for breast cancer.
Treatment: Olaparib · Paclitaxel and Carboplatin — This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 negative (negative)
ER-negative*
Required: HER2 (ERBB2) negative (negative)
HER2-negative**
Required: BRCA1 germline mutation
Germline BRCA (gBRCA) mutation positive
Required: BRCA2 germline mutation
Germline BRCA (gBRCA) mutation positive
Excluded: AR strong expression
TNBC with a non-basal phenotype which strongly expresses Androgen Receptor
Disease stage
Required: Stage INFLAMMATORY CARCINOMA, LOCALLY ADVANCED DISEASE (TNM)
Excluded: Stage T0 TUMOUR IN ABSENCE OF AXILLARY NODE >10MM
T1, T2 or T3 tumours. T4 tumour of any size with direct extension to (a) chest wall or (b) skin. OR Inflammatory carcinoma with tumour of any size. OR Other Locally Advanced Disease: Involvement of ipsilateral large or fixed axillary lymph nodes, or infra or supraclavicular nodes (>10mm diameter or clinical N2 or N3) and primary breast tumour of any diameter. Involvement of ipsilateral large or fixed axillary lymph nodes, or infra or supraclavicular nodes (>10mm diameter, or clinical N2 or N3), without a primary breast tumour identified, the presence of breast cancer in a Lymph Node (LN) must be histopathologically confirmed by LN biopsy.
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Previous or concomitant chemotherapy or biological agents used for the treatment of cancer in the last 5 years
Cannot have received: biological agents
Previous or concomitant chemotherapy or biological agents used for the treatment of cancer in the last 5 years
Lab requirements
Blood counts
adequate bone marrow function required
Kidney function
adequate renal function required
Liver function
adequate hepatic function required
Be fit to receive the trial chemotherapy regimen in the opinion of the responsible clinician: Adequate bone marrow, hepatic, and renal function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03150576 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, biological agents disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 negative is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
Does this trial require BRCA1?
Yes, BRCA1 germline mutation is a required biomarker for enrollment.
Are patients with AR alterations eligible?
No. AR strong expression is an exclusion criterion.
What disease stage is eligible?
Stage INFLAMMATORY CARCINOMA or LOCALLY ADVANCED DISEASE is required.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 16 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages